CELLECTIS' main shareholders are a group of venture capital investors who hold around 52.5% of the company's shares. The Institut Pasteur holds 5.5% and the balance (around 41%) is held by the public (23%) and a number of individuals linked to the company, including its managers and staff (19%).
Annual General Meeting
Cellectis' Annual General Meeting is due to take place on October 30 2008 at the Biocitech site.
Documentation concerning the AGM will be available on site or from the company on request.